Anti-angiogenesis Peptide

血管生成抑肽

Report date: 2022/04/26 15:51:20
NME

Base Information

Drug NameAnti-angiogenesis Peptide
Drug Alias NameFpATFibrinostatin
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionAngiogenesis inhibitors
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsLiver Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Cancer Hospital
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeijing Cancer HospitalBeijing Science Sun Pharmaceutical Co LtdBeijing Institute For Cancer Research
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsLiver Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A